Randomized, open-label, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with rilvegostomig vs standard of care (SOC) in first-line, human epidermal growth factor receptor 2 (HER2)-expressing, locally advanced or metastatic (LA/m) biliary tract cancer (BTC): DESTINY-BTC01

被引：0

作者：

Ikeda, M. ^{[1
]}

Kuang, M. ^{[2
]}

Oh, D-Y. ^{[3
]}

Cohen, G. ^{[4
]}

Raoufmoghaddam, S. ^{[5
]}

Winter, M. ^{[6
]}

Javle, M. ^{[7
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan

[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Guangzhou, Peoples R China

[3] Seoul Natl Univ Hosp, Dept Med, Seoul, South Korea

[4] AstraZeneca, Global Med Dev, Gaithersburg, MD USA

[5] AstraZeneca, Oncol R&D, Cambridge, England

[6] AstraZeneca, Oncol Biometr, Cambridge, England

[7] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX USA

来源：

关键词：

D O I：

10.1016/j.annonc.2024.10.279

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

261TiP

引用

页码：S1501 / S1501

页数：1